Display options
Cite
Park S, Nahmkoong W, Cheon C, et al. Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial. Evid Based Complement Alternat Med. 2013;2013:498935doi: 10.1155/2013/498935.
Park, S., Nahmkoong, W., Cheon, C., Park, J. S., Jang, B. H., Shin, Y., Kim, K. S., Go, H., Song, Y. K., & Ko, S. G. (2013). Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial. Evidence-based complementary and alternative medicine : eCAM, 2013498935. https://doi.org/10.1155/2013/498935
Park, Sunju, et al. "Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial." Evidence-based complementary and alternative medicine : eCAM vol. 2013 (2013): 498935. doi: https://doi.org/10.1155/2013/498935
Park S, Nahmkoong W, Cheon C, Park JS, Jang BH, Shin Y, Kim KS, Go H, Song YK, Ko SG. Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial. Evid Based Complement Alternat Med. 2013;2013:498935. doi: 10.1155/2013/498935. Epub 2013 Aug 26. PMID: 24062784; PMCID: PMC3770019.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2013;2013:498935. doi: 10.1155/2013/498935. Epub 2013 Aug 26.

Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial.

Evidence-based complementary and alternative medicine : eCAM

Sunju Park, Won Nahmkoong, Chunhoo Cheon, Jeong-Su Park, Bo-Hyoung Jang, Yongcheol Shin, Kyung-Soo Kim, Hoyeon Go, Yun-Kyung Song, Seong-Gyu Ko

Affiliations

  1. Department of Preventive Medicine, College of Korean Medicine, Daejeon University, 62 Daehak-ro, Daejeon 300-716, Republic of Korea.

PMID: 24062784 PMCID: PMC3770019 DOI: 10.1155/2013/498935

Abstract

Objective. The purpose of this study was to assess the efficacy and safety of Taeeumjowi-tang (TJ001) as well as to estimate obesity-related factors. Methods. This was a 12-week trial with 5 visits. A total of 102 participants of both genders were randomized to either TJ001 (n = 57) group or the placebo group (n = 55). Subjects were administered 7 g of either TJ001 or placebo 3 times a day. The primary outcome was a rate of subjects who lost 5% or more of initial weight. Secondary outcomes included anthropometric parameters, lipid profiles, and body fat composition. Results. The subject response rate of ≥5% weight loss compared to baseline was similar in both groups, and no statistically significant difference was observed (P = 0.87). Changes in anthropometric parameters were greater during the first 4 weeks in the treatment group (P < 0.0001). There were no significant changes in both within groups and between groups for lipid profile and body fat composition. No adverse event was reported in either group. Conclusion. Although the difference between the groups regarding a rate of subjects who lost 5% or more of initial weight did not show statistical significance, TJ001 appears to be beneficial in safely controlling weight.

References

  1. N Engl J Med. 2010 Sep 2;363(10):905-17 - PubMed
  2. Int J Obes (Lond). 2006 Oct;30(10):1545-56 - PubMed
  3. Hypertens Res. 2006 Feb;29(2):75-80 - PubMed
  4. JAMA. 2003 May 21;289(19):2560-72 - PubMed
  5. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253 - PubMed
  6. Diabetes Metab J. 2012 Feb;36(1):13-25 - PubMed
  7. World J Gastroenterol. 2009 Jul 7;15(25):3073-85 - PubMed
  8. Int J Obes Relat Metab Disord. 2002 May;26(5):593-604 - PubMed
  9. Obes Rev. 2001 Aug;2(3):199-211 - PubMed
  10. Trials. 2012 Apr 07;13:33 - PubMed
  11. Evid Based Complement Alternat Med. 2012;2012:435702 - PubMed

Publication Types